Nausea lacosamide

Lacosamide Enhances slow inactivation of Na + channels blocks effect of neurotrophins (via CRM P-2) Well absorbed minimal protein binding one major nonactive metabolite t /2 12-14 h Generalized tonic-clonic seizures, partial seizures Toxicity Dizziness, headache, nausea small increase in PR interval Interactions Minimal... 

In an open study of lacosamide in 69 patients with painful diabetic neuropathy the initial dose was followed by escalation by 100 mg/day up to a maximum of 400 mg/day [132 ]. Patients then entered a 20-week maintenance period after which they could opt to continue for up to about 2.5 years. The most commonly reported adverse events that were considered possibly related to the trial medication were headache (7%), dizziness (7%), tremor (4%), fatigue (6%), and diarrhea and nausea (4%). The adverse events occurred most often during the titration period. Seven patients withdrew because of adverse effects—electrocardiographic changes (n =2), dizziness and nausea (n = 1), chest pain and nausea (n = 1), dizziness, fatigue, and tinnitus (n = 1), possible stroke and convulsion (n = 1, this was considered a serious adverse event), accidental overdose (n = 1). 

In a multicenter, randomized, placebo-controlled, double-blind trial in 495 patients with painful diabetic neuropathy who took lacosamide 200, 400, or 600 mg/day for 12 weeks after a 6-week titration phase, the lacosamide 400 mg/day group had significant improvement in the primary efficacy measure [136 ]. The most common treatment-emergent adverse events included dizziness, nausea, fatigue, headache, and tremor and all appeared to be dose-related. For example, the incidence of dizziness was 5% at 400 mg/day and 22% at 600 mg/day. There was nausea in 5% of patients taking 400 mg/day and 12% of those taking... 

Lacosamide 200 and 400 mg/day as addon therapy in 485 patients with uncontrolled partial-onset seizures has been studied in a multicenter, double-blind, placebo-con-trolled trial, which consisted of an 8-week baseline, a 4-week titration period, and a 12-week maintenance period [137 ]. The median percentage reduction in seizure frequency was 21% for placebo, 35% for lacosamide 200 mg/day, and 36% for 400 mg/ day. The most clearly dose-related treatment-emergent adverse events included dizziness (17 and 25 patients randomized to 200 or 400 mg of lacosamide respectively), nausea (9 and 13 patients), and vomiting (5 and 9 patients). Diplopia (13 and 16 patients) did not appear to be dose-related. The incidence of somnolence was low (4.3%, 3.8%, and 3.7% in patients randomized to lacosamide 200 mg, 400 mg, and placebo respectively). The experimental drug was withdrawn in 42 patients because of adverse effects eight had been randomized to placebo, 10 to lacosamide 200 mg/day, and 24 to 400 mg/day. The adverse effects... 

Observational studies So-called third generation antiepileptic medications include retigabine, lacosamide, and esli-carbazepine. All three AEDs have linear pharmacokinetics and rapid absorption. The most common adverse effects observed with lacosamide versus placebo were dizziness, headache, diplopia, and nausea with retigabine, they were dizziness, somnolence, and fatigue and with eslicarbazepine acetate, dizziness and somnolence were reported [26 ]. 

Systematic reviews A systemic review and meta-analysis was conducted to evaluate the association of severe adverse effects with lacosamide. The total number of patients included was 3148. The number of side effects associated with lacosamide increased in relation to dose One at 200 mg/day (dizziness) six at 400 mg/day (dizziness, vertigo, abnormal coordination, abnormal vision, nausea, and vomiting) nine at 600 mg/day (dizziness, vertigo, ataxia, balance disorder, diplopia, fatigue, nausea, vomiting, and tremor). The proportion of study withdrawals related to adverse effects also increased significantly with increasing dose... 

---